Application of ulipristal acetate in the preparation of anti-fibrosis drugs
By using uristat acetate as an agonist of FMO2, it promotes FMO2 expression and inhibits fibrosis marker, solves the treatment problem of cardiac fibrosis after myocardial infarction, and achieves effective inhibition of cardiac fibrosis and improves cardiac function, simplifying the Drug development process reduces costs.
Patent Information
- Application Number
- CN202410503460.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-25
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-04-25
AI Technical Summary
The existing technology lacks effective methods to treat cardiac fibrosis after myocardial infarction, which makes the process of heart failure difficult to reverse, and the development steps of new drugs are cumbersome, with long cycles and high costs.
Ulistat acetate, as a new FMO2 agonist, can significantly promote the expression of flavin-containing monooxidase 2 (FMO2), inhibit the expression of TGF-β-induced fibrosis markers and extracellular matrix proteins, thereby effectively inhibiting organ fibers. It has a significant inhibitory effect on cardiac fibrosis, and has no obvious toxic side effects within the effective dose range.
Ulistat acetate significantly reduces cardiac collagen deposition after MI, inhibits cardiac fibrosis, improves cardiac function, and shortens the R&D cycle, reduces costs, and increases output by screening FDA-approved drug databases.
Smart Images

Figure CN118436663B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to application of ulipristal acetate in preparing anti-fibrosis drugs. Background Art
[0002] Fibrosis is scarring and tissue hardening caused by excessive deposition of extracellular matrix proteins by myofibroblasts in response to chronic inflammation. Fibrosis plays a role in the progression of chronic diseases of many organs, including the heart, liver, and lungs.
[0003] Myocardial infarction and subsequent heart failure are one of the main causes of death in patients with cardiovascular diseases. Myocardial cell death after myocardial infarction causes the activation of cardiac fibroblasts. Fibroblasts have a repairing effect, but when they are over-activated and the excessive deposition of secreted extracellular matrix will form fibrotic tissue and eventually lead to heart failure after myocardial infarction. Therefore, how to inhibit the excessive activation of cardiac fibroblasts after myocardial infarction is to improve post-myocardial infarction fibrosis and reduce adverse remodeling is a key scientific issue and clinical need that needs to be solved urgently.
[0004] At present, comprehensive measures such as drugs and interventional therapy have significantly reduced the early mortality rate of myocardial infarction, but there is a lack of effective treatment for pathological fibrosis after myocardial infarction, and the process of heart failure cannot be reversed. Therefore, the development of new anti-fibrosis drugs and new strategies is a major challenge that needs to be solved urgently. Although the mechanism of driving organ-specific fibrosis has not been fully elucidated, the fibrosis of different tissues and organs has persistent abnormal activation of myofibroblasts mediated by multiple signals such as transforming growth factor, platelet-derived growth factor, and fibroblast growth factor, suggesting that anti-fibrosis drugs developed for the above signals have a certain universality. The applicant's previous work found that the content of flavin monooxygenase 2 (FMO2) in cardiac tissue after myocardial infarction was significantly reduced. Downregulating FMO2 in cardiac fibroblasts can lead to impaired cardiac function, increased collagen deposition, and an increase in the number of myofibroblasts, accompanied by activation of the TGFβ1 / Smad3 pathway, suggesting that FMO2 can be used as a target for drugs to treat cardiac fibrosis.
[0005] The development of new drugs often involves many steps, a long cycle, and high costs, while existing drugs are generally safer and have more research materials and clinical data. Using old drugs in new ways is an effective strategy for drug development, which can shorten the development cycle, reduce costs, reduce risks, and increase output. Therefore, screening the FDA-approved drug library has positive significance for the development of drugs that promote FMO2 expression for the treatment of fibrosis. Summary of the invention
[0006] The present invention provides an application of ulipristal acetate in the preparation of an anti-fibrosis drug. The present invention first discovered that ulipristal acetate has the effect of significantly promoting the expression of flavin-containing monooxygenase 2 (FMO2), and can effectively inhibit organ fibrosis. Moreover, ulipristal acetate has no obvious toxic side effects within the effective dose range, and can provide a new solution for the clinical treatment of fibrotic diseases.
[0007] The specific technical scheme of the present invention is:
[0008] In a first aspect, the present invention provides a use of ulipristal acetate in the preparation of a flavin-containing monooxygenase 2 (FMO2) agonist.
[0009] Ulipristal acetate is currently mainly used as an emergency contraceptive drug, and clinical trials have also found that ulipristal acetate has excellent therapeutic effects on uterine fibroids. The present invention team first discovered through experiments that ulipristal acetate has a significant effect on promoting the expression of FMO2, and therefore can be used as a new FMO2 agonist.
[0010] Preferably, the FMO2 is FMO2 in cardiac fibroblasts, dermal fibroblasts or embryonic fibroblasts.
[0011] The present invention team discovered through experiments that ulipristal acetate can reverse the downregulation of FMO2 caused by the TGFβ signaling pathway by promoting the expression level of FMO2 in fibroblasts from different species and organs.
[0012] In a second aspect, the present invention provides use of ulipristal acetate in preparing a medicament for preventing and / or treating fibrosis.
[0013] Based on the applicant's previous discovery that FMO2 can be used as a target for drugs to treat cardiac fibrosis, the present invention found through experiments that ulipristal acetate can effectively inhibit the expression of fibrosis markers (α-SMA) and extracellular matrix proteins (periostin, fibronectin) in primary fibroblasts induced by TGF-β, thereby effectively inhibiting the classical signaling pathway of organ fibrosis, thereby having the effect of inhibiting organ fibrosis. In addition, the present invention also confirms that ulipristal acetate has no obvious toxic side effects within the effective dosage range.
[0014] Preferably, the fibrosis is cardiac fibrosis or skin fibrosis.
[0015] As further preferred, the fibrosis is cardiac fibrosis.
[0016] The present invention finds that ulipristal acetate has a particularly good inhibitory effect on cardiac fibrosis, which is specifically manifested in that it can significantly reduce cardiac collagen deposition after myocardial infarction, thereby inhibiting cardiac fibrosis.
[0017] Preferably, the cardiac fibrosis is cardiac fibrosis caused by ischemic heart disease, hypertensive heart disease, cardiomyopathy, arrhythmia or rheumatic heart disease.
[0018] As further preferred, the cardiac fibrosis is cardiac fibrosis caused by ischemic heart disease.
[0019] The present invention has found through experiments that ulipristal acetate has a good inhibitory effect on cardiac fibrosis caused by ischemic heart disease.
[0020] Preferably, the drug comprises: ulipristal acetate as a main active ingredient, and pharmaceutically acceptable excipients.
[0021] Preferably, the drug is in the form of an oral preparation.
[0022] In a third aspect, the present invention provides a method for inhibiting fibrosis of cardiac fibroblasts in vitro using ulipristal acetate: by treating cardiac fibroblasts cultured in vitro with ulipristal acetate, the expression level of FMO2 in the cardiac fibroblasts is increased, and the expression levels of the fibrosis marker α-SMA and the extracellular matrix proteins periostin and fibronectin are reduced, thereby inhibiting the fibrosis of cardiac fibroblasts.
[0023] Compared with the prior art, the beneficial effects of the present invention are:
[0024] (1) The present invention first discovered that ulipristal acetate has a significant effect in promoting FMO2 expression and can be used as a new FMO2 agonist.
[0025] (2) The present invention further found that ulipristal acetate can effectively inhibit the expression of TGF-β-induced fibroblast fibrosis markers (α-SMA) and extracellular matrix proteins (periostin, fibronectin), thereby effectively inhibiting the classical signaling pathway of organ fibrosis, thereby having the effect of inhibiting organ fibrosis.
[0026] (3) The present invention has confirmed through animal experiments that ulipristal acetate has no obvious toxic side effects within the effective dosage range. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 The top 20 drugs that can increase FMO2 expression were screened from the FDA drug library; Z-Score = (average chemiluminescence value of drug-treated group - average chemiluminescence value of control group) / standard deviation of chemiluminescence value of drug-treated group; Q = P value * total number of drugs / ranking of drug chemiluminescence values; Z-score>0.5 and Q value>1.0 are positive drugs;
[0028] Figure 2 The results are the validation of the effects of different drugs on FMO2 expression in primary cardiac fibroblasts of neonatal rats;
[0029] Figure 3 To investigate the effect of ulipristal acetate on FMO2 expression in fibroblasts from different species and tissues;
[0030] Figure 4 Primary neonatal rat cardiac fibroblasts were treated with ulipristal acetate in vitro, and the expressions of FMO2, fibrosis marker protein α-SMA, and extracellular matrix proteins Periostin and Fibronectin were detected by Western blot. Fibrosis marker protein α-SMA, and extracellular matrix proteins Periostin and Fibronectin were significantly upregulated after TGFβ treatment, and then inhibited after ulipristal acetate treatment; the downregulation of FMO2 after TGFβ treatment was inhibited by ulipristal acetate;
[0031] Figure 5 Primary neonatal rat cardiac fibroblasts were treated with ulipristal acetate in vitro, and the expression of fibrosis marker proteins and extracellular matrix proteins α-SMA, Periostin and Fibronectin were detected by immunofluorescence staining. These proteins were significantly upregulated after TGFβ treatment and inhibited after ulipristal acetate treatment.
[0032] Figure 6 Primary human cardiac fibroblasts were treated with ulipristal acetate in vitro, and the expressions of FMO2, fibrosis marker protein α-SMA, and extracellular matrix proteins Periostin and Fibronectin were detected by Western blot. Fibrosis marker protein α-SMA, and extracellular matrix proteins Periostin and Fibronectin were significantly upregulated after TGFβ treatment, and then inhibited after ulipristal acetate treatment; the downregulation of FMO2 after TGFβ treatment was inhibited by ulipristal acetate;
[0033] Figure 7 Wild-type mice were treated with 0.1 mg / kg ulipristal acetate by intragastric administration every day, and the cardiac fibrosis was detected by Sirius red staining;
[0034] Figure 8 Wild-type mice were treated with 0.1 mg / kg ulipristal acetate by intragastric gavage daily, and cardiac function was examined by cardiac ultrasound;
[0035] Fig. 9After wild-type mice were intragastrically treated with 0.1 mg / kg ulipristal acetate every day, the morphological changes of the liver, kidney, and small intestine were observed by HE staining to evaluate the safety of the drug;
[0036] Fig.10 Wild-type mice were treated with 0.1 mg / kg ulipristal acetate by oral gavage every day, and the safety of the drug was evaluated by serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine (Cr). DETAILED DESCRIPTION
[0037] The present invention is further described below in conjunction with examples. The terms used in the examples of the present invention are intended to describe specific embodiments rather than to limit the scope of protection of the present invention. Without departing from the spirit and scope of the inventive concept, changes and advantages that can be thought of by those skilled in the art are included in the present invention, and the attached claims and any equivalents thereof are the scope of protection of the present invention. The experimental methods described in the following examples, unless otherwise specified, are conventional methods; the reagents and biological materials, unless otherwise specified, can be obtained from commercial channels.
[0038] Overall embodiment
[0039] In a first aspect, the present invention finds that ulipristal acetate has a significant effect of promoting the expression of flavin-containing monooxygenase 2 (FMO2), and thus ulipristal acetate can be used to prepare a FMO2 agonist.
[0040] In some specific embodiments, the FMO2 is flavin-containing monooxygenase 2 (FMO2) in fibroblasts, in particular FMO2 in cardiac fibroblasts, dermal fibroblasts or embryonic fibroblasts.
[0041] Secondly, based on the previous research results of the present invention team (FMO2 can be used as a target for drugs to treat cardiac fibrosis), ulipristal acetate can be used to prepare drugs to prevent and / or treat fibrosis.
[0042] In some specific embodiments, the fibrosis is cardiac fibrosis or skin fibrosis; as a further preference, the fibrosis is cardiac fibrosis.
[0043] In some specific embodiments, the cardiac fibrosis is cardiac fibrosis caused by ischemic heart disease, hypertensive heart disease, cardiomyopathy, arrhythmia or rheumatic heart disease. As a further preference, the cardiac fibrosis is cardiac fibrosis caused by ischemic heart disease.
[0044] In some specific embodiments, the drug includes: ulipristal acetate as a main active ingredient, and pharmaceutically acceptable excipients, etc.
[0045] In some specific embodiments, the drug is in a formulation for oral administration.
[0046] In a third aspect, the present invention provides a method for inhibiting in vitro cardiac fibroblast fibrosis using ulipristal acetate: treating in vitro cultured cardiac fibroblasts with ulipristal acetate to increase the expression level of FMO2 in the cardiac fibroblasts, and reduce the expression of fibrosis marker α-SMA and extracellular matrix proteins periostin and fibronectin, thereby inhibiting the fibrosis of cardiac fibroblasts. Similarly, on this basis, it can also be extended to in vitro dermal fibroblasts or in vitro embryonic fibroblasts. Specific embodiments
[0048] Example 1: Screening of flavin-containing monooxygenase 2 (FMO2) agonists
[0049] The Ulipristal acetate in the present invention, which has the effects of promoting FMO2 expression and anti-fibrosis, is derived from the screening of the FDA drug library. The team of the present invention has learned in the previous research process that increasing the expression of FMO2 in cardiac fibroblasts can improve cardiac function after myocardial infarction, reduce collagen deposition and the number of myofibroblasts, and inhibit the activation of the TGFβ1 / Smad3 pathway. To this end, the team of the present invention used the HiBiT Lytic Detection System and the FMO2-hibit stable transfectant, took Cocl2 as the positive compound, and used the FDA-approved drug library (containing 1,143 compounds) to screen drugs that can increase FMO2 expression through high-throughput screening experiments.
[0050] The specific process is as follows: construct a human dermal fibroblast cell line stably expressing FMO2-Hibit, culture at 3000 cells / 30ul / well in a 384-well plate at 37°C and 5% carbon dioxide for 24 hours, add drugs with a final concentration of 5μM or 400μM cocl2 to the screening system on the second day and continue to culture for 24 hours. After 24 hours of drug treatment, lyse the cells and use the HiBiTLytic Detection System to detect the chemiluminescence value to quantify Hibit expression.
[0051] Figure 1 The following are the screening results using HiBiT Lytic Detection System: the horizontal axis is Z value, Z value = (average chemiluminescence value of drug-treated group - average chemiluminescence value of control group) / chemiluminescence standard of drug-treated group; the vertical axis is -log (Q) value, Q = P value * total number of drugs / drug P value in ascending order; drugs with Z-score>0.5 and Q value>1.0 are positive drugs.
[0052] We selected the TOP20 positive drugs according to the -log(Q) values from large to small, removed antibiotics (cefpodoxime proxetil, sulfapyridine) and drugs with cardiotoxicity (baclofen, indomethacin, chloroquine phosphate, tamoxifen citrate), and the remaining 14 drugs were (nitazoxanide, ulipristal acetate, procyclidine hydrochloride, imiquimod, cefpodoxime proxetil, baclofen, indomethacin, clofazimine, cabozantinib malate, naphazoline hydrochloride, olodaterol, prochlorperazine, ulipristal acetate, chloroquine phosphate, sulfapyridine, tamoxifen citrate, orphenadrine sulfate, ensidipine, cilastatin, and apremilast).
[0053] Example 2: Further verification of the TOP20 compounds screened in Example
[0054] Primary rat cardiac fibroblasts (NRCF) were isolated and cultured in low-glucose DMEM medium containing 10% fetal bovine serum. After the cells were confluent, they were passaged in a 12-well plate at a ratio of 1:2. When the cells grew to 70% confluent, the medium was replaced with serum-free low-glucose DMEM medium and cultured overnight. Then, ulipristal acetate (the same operation was performed for the other 13 compounds) was added to the low-glucose medium (the final drug concentration was 5uM). The control group was cultured for 24 hours with only DMSO. The culture supernatant was discarded, washed twice with PBS buffer, and 100ul / well of RIPA cell lysis buffer containing protease phosphatase inhibitors was added. After standing on ice for 5 minutes, the protein was scraped into a 1.5ml EP tube with a cell scraper, and then it was placed on ice for 15 minutes, and then it was placed in a centrifuge and centrifuged at 12,000g for 10 minutes. After centrifugation, 90ul of the supernatant was taken into a new EP tube. Then the protein concentration was determined by BCA method. After determining the protein concentration, dilute the protein to the same concentration with 2.5X loading buffer containing 2-mercaptoethanol. Then boil the protein in a metal bath at 99℃ for 10 minutes. Then perform Western blot protein electrophoresis and transfer. After transfer, block the PVDF membrane with PBST solution containing 5% bovine serum albumin for 1 hour, then prepare the anti-FMO2 primary antibody (antibody catalog number corresponds to NBP1-85952) with the primary antibody diluent at a volume ratio of 1:1000, incubate overnight at 4℃, recover the primary antibody, wash 5 times with PBST, 3 minutes each time. Then add the prepared HRP-conjugated secondary antibody of the corresponding primary antibody source species. Incubate at room temperature for 1 hour. Discard the secondary antibody and wash 5 times with PBST, 3 minutes each time. Then use the developer to develop the bands. The β-actin internal reference was incubated with HRP direct-labeled antibody (1:6000 dilution) at room temperature for 2 hours, the direct-labeled antibody was discarded, and the sample was washed 5 times with PBST, 3 minutes each time, and then the bands were developed and imaged with developer solution. The gray value was calculated using Image J software.
[0055] Figure 2This is a validation of TOP20 drugs (a total of 14 compounds) in primary cardiac fibroblasts of suckling rats. The experimental results show that 12 of the drugs can induce the expression of FMO2 in primary cardiac fibroblasts of suckling rats, and ulipristal acetate is one of the drugs that increases the expression of FMO2 in TOP2 (the increase is greater than two times). Therefore, the cell experiment in this example further confirms that ulipristal acetate can be used as a new type of FMO2 agonist.
[0056] Example 3: Verification of Ulipristal Acetate Increasing FMO2 Expression in Fibroblasts of Different Species and Tissues
[0057] Human dermal fibroblast cell lines stably expressing FMO2-Hibit, rat primary cardiac fibroblasts (NRCF), mouse embryonic fibroblasts, and isolated human primary cardiac fibroblasts were propagated into 12-well plates. When the cells grew to 70% confluence, the culture medium was replaced with serum-free low-glucose DMEM medium and cultured overnight. The next day, 0 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, and 20 μM ulipristal acetate (T2527, Taoshu Biotechnology) were added and cultured for 24 hours. After 24 hours of drug treatment, the cells were lysed, and the HiBiT Lytic Detection System was used to quantify Hibit expression in the human dermal fibroblast cell line. The protein of the remaining cells was extracted and Western blot experiments were performed (as above) to detect the expression level of FMO2.
[0058] Figure 3 The induction effect of ulipristal acetate on FMO2 in fibroblasts of different species and tissue sources (human dermal fibroblast cell line, rat primary cardiac fibroblasts, mouse embryonic fibroblasts, human primary cardiac fibroblasts) at different concentration gradients; the experimental results show that ulipristal acetate at a concentration of 2.5-5 μM can induce the expression of FMO2 in all the above fibroblasts. Therefore, the cell experiment in this example confirms that ulipristal acetate has a certain universality as a new FMO2 agonist.
[0059] Example 4: Western blot evaluation of the effect of ulipristal acetate on inhibiting the expression of fibrosis markers and extracellular matrix proteins in primary neonatal rat cardiac fibroblasts
[0060] Primary cardiac fibroblasts (NRCF) from neonatal rats were isolated and cultured in high-glucose DMEM medium containing 10% fetal bovine serum. After the cells were confluent, they were passaged in a 12-well plate at a ratio of 1:2. When the cells were 70% confluent, the medium was replaced with serum-free low-glucose DMEM medium and cultured overnight. TGFβ was then added to the low-glucose medium (the final concentration of TGFβ was 20 ng / ml). The control group only added TGFβ solvent. After 24 hours, Ulipristal acetate was added at a final concentration of 5uM. The control group only added DMSO; the two were cultured together for 24 hours. Proteins were extracted for Western blot experiments (same as above). The primary antibody catalog numbers for α-SMA, Periostin, Fibronectin, and FMO2 are ab5694, AF2955, ab2413, and NBP1-85952, respectively).
[0061] Figure 4 In order to verify the effect of ulipristal acetate on fibrosis in vitro using primary neonatal rat cardiac fibroblasts, Western blot results showed that the fibrosis markers α-SMA, Periostin and Fibronectin were significantly upregulated after TGFβ treatment, and were inhibited by about 30-40% after ulipristal acetate treatment. At the same time, ulipristal acetate could also reverse the downregulation of FMO2 after TGFβ treatment, indicating that ulipristal acetate can inhibit the downregulation of FMO2 caused by TGFβ signal activation and inhibit fibrosis at the same time.
[0062] Example 5: Immunofluorescence evaluation of the effect of ulipristal acetate on the expression of fibrosis markers and extracellular matrix proteins in primary neonatal rat cardiac fibroblasts
[0063] Primary rat cardiac fibroblasts (NRCF) were isolated and cultured in high-glucose DMEM medium containing 10% fetal bovine serum. After the cells were confluent, they were passaged in a 24-well plate at a ratio of 1:2. When the cells grew to 70% confluent, the medium was replaced with serum-free low-glucose DMEM medium and cultured overnight. Then TGFβ was added to the low-glucose medium (the final concentration of TGFβ was 20ng / ml). The control group only added TGFβ solvent. After 24 hours, Ulipristal acetate was added at a final concentration of 5uM, and the control group only added DMSO; the two were cultured together for 24 hours. The culture supernatant was discarded, washed twice with PBS buffer, fixed with 4% paraformaldehyde at room temperature for 10 minutes, washed three times with PBS buffer, and permeabilized with 0.5% Triton X-100 (prepared with 1xPBS) at room temperature for 20 minutes; after washing three times with PBS, the cells were blocked with goat serum at room temperature for 30 minutes, and the primary antibody was diluted to the target ratio with antibody diluent, and incubated overnight at 4℃. The next day, take out the wet box and rewarm for 30 minutes, then wash with PBS three times, 5 minutes each time; fluorescent secondary antibody: dilute the fluorescent secondary antibody with antibody diluent, incubate at room temperature in the dark for 2 hours, wash with PBS three times, seal the slide with DAPI staining solution containing anti-quenching agent, dry the slide, and observe under a microscope to obtain fluorescent images.
[0064] Figure 5 In order to verify the regulatory effect of ulipristal acetate on fibrosis in primary neonatal rat cardiac fibroblasts in vitro by immunofluorescence staining, the fluorescence results showed that the fluorescence intensity (green) of the fibrosis marker protein α-SMA and the extracellular matrix proteins Periostin and Fibronectin was significantly upregulated after TGFβ signal activation. It was inhibited by ulipristal acetate treatment (about 50%), indicating that ulipristal acetate can inhibit the activation of cardiac fibroblasts.
[0065] Example 6: Evaluation of the effect of ulipristal acetate in inhibiting the expression of fibrosis markers and extracellular matrix proteins in primary human cardiac fibroblasts
[0066] Human primary cardiac fibroblasts (NRCF) were isolated and cultured in DMEM / F12 medium containing 10% fetal bovine serum. After the cells were confluent, they were passaged in a 12-well plate at a ratio of 1:2. When the cells grew to 70% confluent, the medium was replaced with serum-free DMEM / F12 medium and cultured overnight. Then TGFβ was added to the medium (the final concentration of TGFβ was 20ng / ml). The control group only added TGFβ solvent. After 24 hours, Ulipristal acetate was added at a final concentration of 5uM. The control group only added DMSO; the two were cultured together for 24 hours. Proteins were extracted for Western blot experiments (same as above). The primary antibody catalog numbers of aSMA, Periostin, Fibronectin and FMO2 are ab5694, AF2955, ab2413 and NBP1-85952, respectively).
[0067] Figure 6 In order to verify the effect of ulipristal acetate on fibrosis in vitro using primary human cardiac fibroblasts, Western blot results showed that the fibrosis markers α-SMA, Periostin and Fibronectin were significantly upregulated after TGFβ treatment, and then inhibited after ulipristal acetate treatment. At the same time, ulipristal acetate could also reverse the downregulation of FMO2 after TGFβ treatment, indicating that ulipristal acetate can inhibit the downregulation of FMO2 caused by TGFβ signal activation and inhibit fibrosis at the same time.
[0068] Example 7: Evaluation of cardiac fibrosis and cardiac function in mice with myocardial infarction treated with ulipristal acetate
[0069] Eight-week-old C57 mice were used for myocardial infarction modeling and then randomly divided into two groups, with 6 mice in each group. Cardiac ultrasound contractile function evaluation was performed 3 days after modeling to ensure that there was no difference in baseline cardiac function between the two groups. The experimental group was given 0.1 mg / kg of ulipristal acetate by oral gavage every day, and the control group was injected with an equal amount of ulipristal acetate solvent each time. Samples were collected 4 weeks after modeling, and gross images of the mouse heart were taken. The heart was fixed and dehydrated and then embedded. Then 4um thick paraffin sections were made, starting from the apex of the heart, and sections were collected when the ring-shaped tissue structure appeared. One section was collected every 500um, and 5 levels were collected for each heart. Sirius red staining was then performed, and the proportion of infarct fibrosis area was statistically analyzed using Image J software.
[0070] Figure 7 Wild-type mice were treated with 0.1 mg / kg ulipristal acetate by gavage every day 3 days after myocardial infarction surgery. Samples were collected 28 days after surgery, and the effect of ulipristal acetate on cardiac fibrosis after myocardial infarction was observed by Sirius red staining of heart sections. The staining results showed that the area of fibrosis after ulipristal acetate treatment was reduced by about 30% compared with the control group, indicating that ulipristal acetate can reduce cardiac fibrosis after myocardial infarction.
[0071] Example 8: Evaluation of cardiac function in mice with myocardial infarction treated with ulipristal acetate
[0072] Eight-week-old C57 mice were used for myocardial infarction modeling and then randomly divided into two groups, with 6 mice in each group. The cardiac ultrasound contractile function was evaluated 3 days after modeling to ensure that there was no difference in baseline cardiac function between the two groups. The experimental group was given 0.1 mg / kg of ulipristal acetate by gavage every day, and the control group was injected with an equal amount of ulipristal acetate solvent each time. Ultrasound cardiac contractile function was evaluated 14 and 28 days after modeling.
[0073] Figure 8 Wild-type mice were treated with 0.1 mg / kg ulipristal acetate by intragastric administration 3 days after myocardial infarction surgery. The left ventricular ejection fraction was measured by cardiac ultrasound before myocardial infarction and 3, 14, and 28 days after myocardial infarction. Figure 8 As shown, 14 and 28 days after myocardial infarction, the left ventricular ejection fraction in the ulipristal acetate treatment group was higher than that in the control group and the difference was statistically significant, indicating that ulipristal acetate has the effect of improving cardiac function after myocardial infarction.
[0074] Example 9: HE staining to evaluate the toxicity and side effects of ulipristal acetate on mice
[0075] When the mice were collected after the myocardial infarction model was established for 28 days and the ulipristal acetate treatment was completed in Example 7-8, the kidneys, livers and small intestines of the mice were taken, fixed and dehydrated, and then embedded, and paraffin sections with a thickness of 4 microns were made. After the sections were dewaxed, HE staining was performed using a fully automatic staining machine, and the sections were sealed with neutral gum and photographed using a Leica upright microscope.
[0076] Fig. 9 Wild-type mice were given 0.1 mg / kg ulipristal acetate by gavage every day 3 days after myocardial infarction surgery. Samples were collected 28 days after surgery, and the safety of the drug was evaluated by HE staining of liver, kidney, and small intestine sections to observe whether there were pathological changes such as vacuolar degeneration, pigment deposition, cell necrosis, and inflammatory cell infiltration. The staining results in the figure indicate that ulipristal acetate has no obvious toxic side effects on mice at an effective anti-fibrosis dose and has good biosafety.
[0077] Example 10: Evaluation of the toxic and side effects of ulipristal acetate on mice by blood biochemical detection
[0078] When the mice in Example 7-8 were subjected to myocardial infarction modeling for 4 weeks and completed the treatment with ulipristal acetate, blood was collected into a 1.5 ml EP tube, left to stand at room temperature for 2 hours until the blood coagulated, and then centrifuged at 4°C, 3000 rpm for 10 min to obtain the upper serum, and the levels of creatinine (Cr), urea nitrogen (BUN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured using an automatic biochemical analyzer.
[0079] Fig.10 Wild-type mice were given 0.1 mg / kg ulipristal acetate by oral gavage every day 3 days after myocardial infarction surgery. Samples were collected 28 days after surgery to detect serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea nitrogen (BUN), and creatinine (Cr) levels. Compared with the control group, there were no significant differences in the above blood biochemical indicators in the drug-treated group, indicating that ulipristal acetate had no effect on the liver and kidney function of mice at an effective anti-fibrotic dose and had good biosafety.
[0080] The raw materials and equipment used in the present invention, unless otherwise specified, are all commonly used raw materials and equipment in the art; the methods used in the present invention, unless otherwise specified, are all conventional methods in the art.
[0081] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any way. Any simple modification, change and equivalent transformation made to the above embodiment based on the technical essence of the present invention still falls within the protection scope of the technical solution of the present invention.
Claims
1. Use of ulipristal acetate in the preparation of a medicament for preventing and / or treating cardiac fibrosis.
2. The use according to claim 1, characterized in that: The medicine comprises: ulipristal acetate as a main active ingredient and pharmaceutically acceptable excipients.
3. The use according to claim 2, characterized in that: The drug is in the form of an oral preparation.
4. A method for inhibiting in vitro cardiac fibroblast fibrosis using ulipristal acetate, characterized in that: By treating cardiac fibroblasts cultured in vitro with ulipristal acetate, the expression level of FMO2 in cardiac fibroblasts was increased, and the expression levels of fibrosis marker α-SMA and extracellular matrix proteins periostin and fibronectin were reduced, thereby inhibiting the fibrosis of cardiac fibroblasts.
5. Use of ulipristal acetate in inhibiting in vitro cardiac fibroblast fibrosis, characterized in that: By treating cardiac fibroblasts cultured in vitro with ulipristal acetate, the expression level of FMO2 in cardiac fibroblasts was increased, and the expression levels of fibrosis marker α-SMA and extracellular matrix proteins periostin and fibronectin were reduced, thereby inhibiting the fibrosis of cardiac fibroblasts.
Citation Information
Patent Citations
Application of flavin-containing monooxygenase 2 in preparation of medicines treating cardiac disease
CN109200276A
Polypeptide and application thereof in preparation of anti-fibrosis drugs
CN116655746A
Application of fexofenadine hydrochloride in preparation of anti-fibrosis drugs
CN118436646A
Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
US20140271923A1
Progesteron receptor modulators for use in the therapy of uterine fibroids
US20160038510A1
